Stocktoria
REGENXBIO Inc. RGNX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2015-09-17
REGENXBIO Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $170.4M | $83.3M | $90.2M | $112.7M | $470.3M |
| R&D expense | $228.3M | $208.5M | $232.3M | $242.5M | $181.4M |
| Operating income | -$161.2M | -$233.3M | -$268.1M | -$262.9M | $160.0M |
| Interest expense | — | — | $6.9M | $23.3M | $26.3M |
| Income tax | $0 | $0 | -$152,000 | -$84,000 | $13.4M |
| Net income | -$193.9M | -$227.1M | -$263.5M | -$280.3M | $127.8M |
| EPS (diluted) | $-3.76 | $-4.59 | $-6.02 | $-6.50 | $2.91 |
| Operating cash flow | -$124.0M | -$173.1M | -$218.4M | -$207.5M | $218.9M |
| Free cash flow | -$126.4M | -$175.6M | -$228.4M | -$238.2M | $134.7M |
| Cash & equivalents | $34.5M | $57.5M | $34.5M | $97.0M | $345.2M |
| Total assets | $453.0M | $466.0M | $574.0M | $833.3M | $1.1B |
| Total liabilities | $350.3M | $206.3M | $262.2M | $317.1M | $349.6M |
| Shareholders' equity | $102.7M | $259.7M | $311.7M | $516.2M | $764.3M |
Source: SEC EDGAR filings · CIK 0001590877 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.